Growth Hormone

Anamorelin

An orally bioavailable selective ghrelin-receptor agonist investigated in cancer-cachexia research-stage trials for appetite stimulation and lean-mass preservation.

Also known as: ONO-7643

Research consideration: Oral capsule — no reconstitution required. Dose stored in mcg for schema consistency (50,000 mcg = 50 mg).

Quick facts

Molecular weight

547 Da

Half-life

7 h

Frequency

daily

Admins / wk

Routes

Oral

Typical dose

50.0 mg–100 mg

Mechanism & positioning

An orally bioavailable selective ghrelin-receptor agonist investigated in cancer-cachexia research-stage trials for appetite stimulation and lean-mass preservation.

Researched for: ghrelin receptor agonism, appetite and lean-mass research.

Calculate with this peptide

References

Garcia JM et al., Lancet Oncol, 2015.

Related peptides in the Growth Hormone class

Frequently asked questions about Anamorelin

What is the typical research dose range for Anamorelin?

Anamorelin is most commonly investigated at 50.0 mg–100 mg per administration, daily. Note: oral capsule, mg-scale. These values reflect documented research-stage protocols and are not medical recommendations.

What is the half-life of Anamorelin?

Anamorelin has an approximate plasma half-life of 7 hours. Practical steady state is reached after roughly five half-lives — about 1 days under continuous administration.

How is Anamorelin administered in research protocols?

Published research uses oral administration. No reconstitution required — see the profile notes for delivery details.

What vial sizes are commonly available for Anamorelin?

Common stocked vial sizes are 50 mg, 100 mg. The 50 mg vial is the most-used default in published protocols.

Anything important to know about Anamorelin before designing a protocol?

Oral capsule — no reconstitution required. Dose stored in mcg for schema consistency (50,000 mcg = 50 mg).